Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

In this week’s S&P 500 healthcare earnings roundup, 21 of 24 companies beat earnings expectations, while three fell short. On the revenue front, seven missed Wa ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Medicare kickbacks alleged, Joann store closures, and more business headlines. Read the latest news and updates here.